Phillips Wealth Planners LLC Invests $247,000 in Zoetis Inc. (NYSE:ZTS)

Phillips Wealth Planners LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,503 shares of the company’s stock, valued at approximately $247,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Bank Pictet & Cie Europe AG lifted its stake in Zoetis by 5.4% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company’s stock worth $68,354,000 after acquiring an additional 21,470 shares during the period. Sigma Planning Corp lifted its stake in Zoetis by 4.3% in the fourth quarter. Sigma Planning Corp now owns 3,367 shares of the company’s stock worth $549,000 after acquiring an additional 140 shares during the period. IFP Advisors Inc lifted its stake in Zoetis by 13.0% in the fourth quarter. IFP Advisors Inc now owns 10,033 shares of the company’s stock worth $1,635,000 after acquiring an additional 1,158 shares during the period. Finally, Lake Street Advisors Group LLC lifted its stake in Zoetis by 3.1% in the fourth quarter. Lake Street Advisors Group LLC now owns 11,186 shares of the company’s stock worth $1,823,000 after acquiring an additional 341 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Monday, May 12th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $212.13.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Zoetis Stock Performance

Shares of ZTS stock opened at $157.41 on Thursday. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a market cap of $70.08 billion, a PE ratio of 28.26, a price-to-earnings-growth ratio of 2.62 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The company’s fifty day moving average price is $160.10 and its 200-day moving average price is $163.02.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Friday, July 18th. Zoetis’s payout ratio is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.